{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:50:34Z","timestamp":1790250634997,"version":"4.1.0"},"reference-count":134,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite the availability of an effective vaccine against hepatitis B virus (HBV), chronic infection with the virus remains a major global health concern. Current drugs against HBV infection are limited by emergence of resistance and rarely achieve complete viral clearance. This has prompted vigorous research on developing better drugs against chronic HBV infection. Advances in understanding the life cycle of HBV and improvements in gene-disabling technologies have been impressive. This has led to development of better HBV infection models and discovery of new drug candidates. Ideally, a regimen against chronic HBV infection should completely eliminate all viral replicative intermediates, especially covalently closed circular DNA (cccDNA). For the past few decades, nucleic acid-based therapy has emerged as an attractive alternative that may result in complete clearance of HBV in infected patients. Several genetic anti-HBV strategies have been developed. The most studied approaches include the use of antisense oligonucleotides, ribozymes, RNA interference effectors and gene editing tools. This review will summarize recent developments and progress made in the use of gene therapy against HBV.<\/jats:p>","DOI":"10.3390\/ijms160817589","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T10:12:24Z","timestamp":1438337544000},"page":"17589-17610","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Progress and Prospects of Anti-HBV Gene Therapy Development"],"prefix":"10.3390","volume":"16","author":[{"given":"Mohube","family":"Maepa","sequence":"first","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, Wits 2050, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilke","family":"Roelofse","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, Wits 2050, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Ely","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, Wits 2050, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Arbuthnot","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences Faculty, University of the Witwatersrand, Wits 2050, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4254\/wjh.v4.i3.74","article-title":"Hepatitis B: Epidemiology and prevention in developing countries","volume":"4","author":"Franco","year":"2012","journal-title":"World J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2015.01.020","article-title":"Causes of death in people with chronic HBV infection: A population-based cohort study","volume":"62","author":"Montuclard","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1478-3231.2004.0966.x","article-title":"Exploiting the RNA interference pathway to counter hepatitis B virus replication","volume":"25","author":"Arbuthnot","year":"2005","journal-title":"Liver Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/rmv.705","article-title":"Countering hepatitis B virus infection using RNAi: How far are we from the clinic?","volume":"21","author":"Ivacik","year":"2011","journal-title":"Rev. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dkg163","article-title":"Hepatitis B virus: Old, new and future approaches to antiviral treatment","volume":"51","author":"Karayiannis","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jgh.12718","article-title":"Long-term lamivudine treatment achieves regression of advanced liver fibrosis\/cirrhosis in patients with chronic hepatitis B","volume":"30","author":"Xu","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4254\/wjh.v7.i2.150","article-title":"Gene therapeutic approaches to inhibit hepatitis B virus replication","volume":"7","author":"Gebbing","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.str.2013.06.013","article-title":"Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure","volume":"21","author":"Katen","year":"2013","journal-title":"Structure"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antivir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.bmcl.2014.07.032","article-title":"A new series of HAPs as anti-HBV agents targeting at capsid assembly","volume":"24","author":"Yang","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1128\/JVI.03540-12","article-title":"Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide","volume":"87","author":"Yan","year":"2013","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1128\/JVI.03533-12","article-title":"Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of tupaia hepatocytes","volume":"87","author":"Zhong","year":"2013","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3390\/ijms15022892","article-title":"NTCP and beyond: Opening the door to unveil hepatitis B virus entry","volume":"15","author":"Watashi","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/oli.2011.0280","article-title":"Antisense oligonucleotides targeting abhydrolase domain containing 2 block human hepatitis B virus propagation","volume":"21","author":"Ding","year":"2011","journal-title":"Oligonucleotides"},{"key":"ref_18","first-page":"1","article-title":"MicroRNA biogenesis and function: An overview","volume":"700","author":"Ketting","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/nar\/gki155","article-title":"Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides","volume":"33","author":"Hasselblatt","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cca.2005.11.023","article-title":"Ribozyme: A clinical tool","volume":"367","author":"Khan","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev.biophys.30.1.457","article-title":"Ribozyme structures and mechanisms","volume":"30","author":"Doherty","year":"2001","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1087057112463066","article-title":"Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line","volume":"18","author":"Zhao","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12013-014-9847-1","article-title":"Inhibition of hepatitis B virus cccDNA by siRNA in transgenic mice","volume":"69","author":"Li","year":"2014","journal-title":"Cell Biochem. Biophys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2014.02.099","article-title":"TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus","volume":"446","author":"Wu","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","article-title":"The CRISPR-cas9 system inactivates latent HIV-1 proviral DNA","volume":"12","author":"Zhu","year":"2015","journal-title":"Retrovirology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR-cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/gt.2015.2","article-title":"Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)\/CRISPR-associated Cas9 system to disrupt the hepatitis B virus","volume":"22","author":"Zhen","year":"2015","journal-title":"Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ijc.28704","article-title":"Antisense oligonucleotides against TNFR1 prevent toxicity of TNF\/IFN\u03b3 treatment in mouse tumor models","volume":"135","author":"Vandenbroucke","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1099\/0022-1317-71-12-3021","article-title":"Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen","volume":"71 Pt 12","author":"Goodarzi","year":"1990","journal-title":"J. Gen. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1016\/S0021-9258(18)42295-8","article-title":"Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides","volume":"267","author":"Wu","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/j.1460-2075.1993.tb05767.x","article-title":"In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides","volume":"12","author":"Offensperger","year":"1993","journal-title":"EMBO J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2893.1996.tb00076.x","article-title":"In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice","volume":"3","author":"Yao","year":"1996","journal-title":"J. Viral Hepat."},{"key":"ref_35","first-page":"35","article-title":"Inhibition of hepatitis B virus in vitro by antisense oligonucleotides","volume":"40","author":"Yao","year":"1996","journal-title":"Acta Virol."},{"key":"ref_36","first-page":"900","article-title":"Inhibition of hepatitis B virus (HBV) replication using antisense LNA targeting to both S and C genes in HBV","volume":"17","author":"Deng","year":"2009","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0166-3542(95)00050-V","article-title":"Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro","volume":"28","author":"Korba","year":"1995","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/hep.510230601","article-title":"Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro","volume":"23","author":"Nakazono","year":"1996","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen\u2014A phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"Meenken","year":"1999","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/bc025559y","article-title":"Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus","volume":"13","author":"Jensen","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1021\/jm9013295","article-title":"Antisense oligonucleotides containing conformationally constrained 2\u2032,4\u2032-(N-methoxy)aminomethylene and 2\u2032,4\u2032-aminooxymethylene and 2\u2032-O,4\u2032-C-aminomethylene bridged nucleoside analogues show improved potency in animal models","volume":"53","author":"Prakash","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_42","first-page":"828","article-title":"Antiviral effects of dual-target antisense LNA by cationic liposomes in transgenic mice","volume":"30","author":"Deng","year":"2013","journal-title":"Sheng Wu Yi Xue Gong Cheng Xue Za Zhi"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1093\/hmg\/ddu349","article-title":"Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity","volume":"23","author":"Sun","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"ref_45","first-page":"1111","article-title":"Transfection and anti-HBV effect mediated by the hepatocytes-targeting cationic liposomes co-modified with \u03b2-sitosterol-\u03b2-d-glucoside and Brij 35","volume":"41","author":"Zhang","year":"2006","journal-title":"Yao Xue Xue Bao"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/sj.gt.3301464","article-title":"Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver","volume":"8","author":"Robaczewska","year":"2001","journal-title":"Gene Ther."},{"key":"ref_47","first-page":"463","article-title":"Targeted polynucleotides for inhibition of hepatitis B and C viruses","volume":"42","author":"Wu","year":"2001","journal-title":"Croat. Med. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1743-422X-7-61","article-title":"Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus","volume":"7","author":"Wang","year":"2010","journal-title":"Virol. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/jmbi.2000.3560","article-title":"Structure and function of the hairpin ribozyme","volume":"297","author":"Fedor","year":"2000","journal-title":"J. Mol. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3390\/v6062376","article-title":"Engineered RNase P ribozymes effectively inhibit human cytomegalovirus gene expression and replication","volume":"6","author":"Yang","year":"2014","journal-title":"Viruses"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2174\/1566524043360410","article-title":"Ribozymes in the age of molecular therapeutics","volume":"4","author":"Bagheri","year":"2004","journal-title":"Curr. Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/mt.2013.37","article-title":"Inhibition of hepatitis B virus gene expression and replication by ribonuclease P","volume":"21","author":"Xia","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v8.i1.91","article-title":"Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro","volume":"8","author":"Song","year":"2002","journal-title":"World J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/sj.gt.3300441","article-title":"Intracellular application of hairpin ribozyme genes against hepatitis B virus","volume":"4","author":"Welch","year":"1997","journal-title":"Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1006\/bbrc.2000.2209","article-title":"In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells","volume":"268","author":"Passman","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2893.2005.00612.x","article-title":"Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes","volume":"12","author":"Nash","year":"2005","journal-title":"J. Viral Hepat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2893.2002.00383.x","article-title":"Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA","volume":"9","author":"Morrissey","year":"2002","journal-title":"J. Viral Hepat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1515\/BC.2001.077","article-title":"Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(a) signal sequence in cultured cells","volume":"382","author":"Feng","year":"2001","journal-title":"Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1046\/j.1440-1746.2001.02548.x","article-title":"Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes","volume":"16","author":"Feng","year":"2001","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ymthe.2003.12.013","article-title":"A self-processing ribozyme cassette: Utility against human papillomavirus 11 E6\/E7 mRNA and hepatitis B virus","volume":"9","author":"Pan","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.virusres.2005.06.005","article-title":"Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis delta virus","volume":"114","author":"Li","year":"2005","journal-title":"Virus Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3748\/wjg.v6.i3.377","article-title":"Construction of HBV-specific ribozyme and its recombinant with HDV and their cleavage activity in vitro","volume":"6","author":"Wen","year":"2000","journal-title":"World J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/108729002320351575","article-title":"Intracellular inhibition of hepatitis B virus S gene expression by chimeric DNA-RNA phosphorothioate minimized ribozyme","volume":"12","author":"Tan","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1006\/bbrc.1997.6099","article-title":"A minimised hammerhead ribozyme with activity against interleukin-2 in human cells","volume":"231","author":"Sioud","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1073\/pnas.89.13.5710","article-title":"Minimal sequence requirements for ribozyme activity","volume":"89","author":"McCall","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/oli.2006.0049","article-title":"Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors","volume":"17","author":"Weinberg","year":"2007","journal-title":"Oligonucleotides"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2144\/97222rr03","article-title":"Design and preparation of a multimeric self-cleaving hammerhead ribozyme","volume":"22","author":"Ruiz","year":"1997","journal-title":"BioTechniques"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: Target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.febslet.2005.08.079","article-title":"Dicing and slicing: The core machinery of the rna interference pathway","volume":"579","author":"Hammond","year":"2005","journal-title":"FEBS Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tree.2008.06.005","article-title":"Origins and evolution of eukaryotic RNA interference","volume":"23","author":"Shabalina","year":"2008","journal-title":"Trends Ecol. Evol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12041-010-0073-3","article-title":"Application of RNA interference in treating human diseases","volume":"89","author":"Angaji","year":"2010","journal-title":"J. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1126\/science.1252967","article-title":"RNA interference. Drugging RNAi","volume":"347","author":"Haussecker","year":"2015","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2013.09.050","article-title":"5\u2032-Triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells","volume":"721","author":"Chen","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/cbic.201402551","article-title":"Base modification strategies to modulate immune stimulation by an siRNA","volume":"16","author":"Valenzuela","year":"2015","journal-title":"ChemBioChem"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1021\/bi500602z","article-title":"Structure-based design of novel chemical modification of the 3\u2032-overhang for optimization of short interfering RNA performance","volume":"54","author":"Xu","year":"2015","journal-title":"Biochemistry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/hepr.12189","article-title":"Targeted delivery of siRNA against hepatitis B virus by preS1 peptide molecular ligand","volume":"44","author":"Huang","year":"2014","journal-title":"Hepatol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11095-011-0554-y","article-title":"Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles","volume":"29","author":"Kong","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-4939-1538-5_10","article-title":"Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes","volume":"1218","author":"Sebestyen","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_81","unstructured":"Arrowhead Presents Data on ARC-520 and ARC-AAT at AASLD the Liver Meeting\u00ae 2014. Available online: http:\/\/ir.arrowheadresearch.com\/releasedetail.cfm?releaseid=881791."},{"key":"ref_82","unstructured":"Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees. Available online: http:\/\/investors.alnylam.com\/releasedetail.cfm?ReleaseID=847055."},{"key":"ref_83","unstructured":"Tekmira Presents Results of Preclinical Studies with Hepatitis B Therapeutic, Available online: http:\/\/www.sec.gov\/Archives\/edgar\/data\/1447028\/000117184314004780\/newsrelease.htm."},{"key":"ref_84","unstructured":"Tekmira Initiates Phase I Clinical Trial of TKM-HBV. Available online: http:\/\/investor.tekmirapharm.com\/releasedetail.cfm?ReleaseID=892233."},{"key":"ref_85","unstructured":"Evaluation of TT-034: Safe and Durable Hepatic Expression of Anti-HCV ShRNA in a Non-Human Primate Model. Available online: http:\/\/www.benitec.com\/documents\/1311_tt_presn_hcv_aasld.pdf."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/hum.2012.239","article-title":"Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference","volume":"24","author":"Sun","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1172\/JCI43565","article-title":"Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver","volume":"120","author":"Grimm","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/nar\/gkp446","article-title":"Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles","volume":"37","author":"Ely","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/mt.2008.82","article-title":"Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo","volume":"16","author":"Ely","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/gt.2014.94","article-title":"Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses","volume":"22","author":"Ivacik","year":"2015","journal-title":"Gene Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"718743","DOI":"10.1155\/2014\/718743","article-title":"Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter","volume":"2014","author":"Mowa","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2008.144","article-title":"Expression of shRNA from a tissue-specific Pol II promoter is an effective and safe RNAi therapeutic","volume":"16","author":"Giering","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR-cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1172\/JCI72992","article-title":"Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9","volume":"124","author":"Gupta","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3198","article-title":"Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells","volume":"33","author":"Chu","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: Prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-biochem-010909-095056","article-title":"The discovery of zinc fingers and their applications in gene regulation and genome manipulation","volume":"79","author":"Klug","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ymthe.2005.06.094","article-title":"Custom zinc-finger nucleases for use in human cells","volume":"12","author":"Alwin","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10529-014-1690-3","article-title":"A suicidal zinc finger nuclease expression coupled with a surrogate reporter for efficient genome engineering","volume":"37","author":"Zhang","year":"2015","journal-title":"Biotechnol. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nature07845","article-title":"High-frequency modification of plant genes using engineered zinc-finger nucleases","volume":"459","author":"Townsend","year":"2009","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/pcp\/pcu170","article-title":"Genome editing with engineered nucleases in plants","volume":"56","author":"Osakabe","year":"2015","journal-title":"Plant Cell Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10126-014-9587-7","article-title":"Gene replacement by zinc finger nucleases in medaka embryos","volume":"16","author":"Guan","year":"2014","journal-title":"Mar. Biotechnol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/dvg.22422","article-title":"Engineering subtle targeted mutations into the mouse genome","volume":"51","author":"Menke","year":"2013","journal-title":"Genesis"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1128\/JVI.00366-08","article-title":"Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture","volume":"82","author":"Zimmerman","year":"2008","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1101\/gr.099747.109","article-title":"Targeted chromosomal deletions in human cells using zinc finger nucleases","volume":"20","author":"Lee","year":"2010","journal-title":"Genome Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1101\/gr.129635.111","article-title":"Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases","volume":"22","author":"Lee","year":"2012","journal-title":"Genome Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1101\/gr.122879.111","article-title":"Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme","volume":"22","author":"Wang","year":"2012","journal-title":"Genome Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nbt0605-686","article-title":"\u201cMagic\u201d scissors for genome surgery","volume":"23","author":"Kandavelou","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature03556","article-title":"Highly efficient endogenous human gene correction using designed zinc-finger nucleases","volume":"435","author":"Urnov","year":"2005","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/bit.24890","article-title":"Transcription activator-like effector nucleases (TALENs): A highly efficient and versatile tool for genome editing","volume":"110","author":"Sun","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: A widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1093\/nar\/gkt754","article-title":"Directed evolution of the TALE N-terminal domain for recognition of all 5\u2032 bases","volume":"41","author":"Lamb","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2014.12.036","article-title":"Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN","volume":"205","author":"Ain","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e1000869","DOI":"10.1371\/journal.pgen.1000869","article-title":"KRAB-zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading","volume":"6","author":"Groner","year":"2010","journal-title":"PLoS Genet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1128\/MCB.00487-06","article-title":"The KAP1 corepressor functions to coordinate the assembly of de novo HP1-demarcated microenvironments of heterochromatin required for KRAB zinc finger protein-mediated transcriptional repression","volume":"26","author":"Sripathy","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tim.2014.01.007","article-title":"To acquire or resist: The complex biological effects of CRISPR-Cas systems","volume":"22","author":"Davidson","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mib.2014.02.007","article-title":"Gene regulation by engineered CRISPR-Cas systems","volume":"18","author":"Fineran","year":"2014","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1440-1746.2010.06546.x","article-title":"Hepatitis B virus X protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma","volume":"26","author":"Kew","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e97579","DOI":"10.1371\/journal.pone.0097579","article-title":"AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/mt.2013.212","article-title":"An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases","volume":"22","author":"Chen","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR-cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting hepatitis B virus with CRISPR-cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR-cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1128\/JVI.01024-14","article-title":"Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice","volume":"88","author":"Qi","year":"2014","journal-title":"J. Virol."},{"key":"ref_133","unstructured":"Kinetics of Knockdown from RNAi Therapeutic ARC-520 on HBV RNA, DNA and Antigens in Mice and Chimpanzees. Available online: http:\/\/www.arrowheadresearch.com\/sites\/default\/files\/MolBiol_HBV_poster_102313.pdf."},{"key":"ref_134","first-page":"217","article-title":"Combinatorial effects of ST6Gal I siRNA and antisense oligonucleotide-mediated gene silence on metastasis ability of cervical carcinoma cells","volume":"38","author":"Yuan","year":"2007","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/8\/17589\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:59Z","timestamp":1760215799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/8\/17589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":134,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8]]}},"alternative-id":["ijms160817589"],"URL":"https:\/\/doi.org\/10.3390\/ijms160817589","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,31]]}}}